BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Borsa Italiana 07:05:04 2024-06-06 EDT | ||
| 2.855 EUR | +0.53% |
|
| Current month | +15.45% | ||
| 1 month | +21.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 2.855 | +0.53% |
| 24-06-05 | 2.84 | +4.22% |
| 24-06-04 | 2.725 | +3.81% |
| 24-06-03 | 2.625 | +6.71% |
| 24-05-31 | 2.46 | +10.56% |
Real-time Borsa Italiana
Last update June 06, 2024 at 07:05 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S35330 | |
| ISIN | DE000SW890R1 |
| Date issued | 2024-04-23 |
| Strike | 10,217 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.875 € |
|---|---|
| Lowest since issue | 1.374 € |
| Spread | 0.01 € |
| Spread % | 0.35% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
172.9
USD
Spread / Average Target
+8.19%
- Stock Market
- Certificates
- S35330 Certificat
